Key Dates
6 May 2008
Notification of Acceptances
26 May 2008
Early Registration Cut-off Date
9 June 2008
Late breaking Abstract Submission Date
2 July 2008
Pre & Post Congress Tours
2 July 2008
Social Program Bookings
2 July 2008
Congress Day Tours
9 July 2008
Accommodation Bookings
9 July 2008
Accommodation Deposit deadline
9-10 August 2008
Postgraduate Weekend Courses
10-14 August 2008
Congress Opens
With thanks to
Allan D. Kirk, MD, PhD
Allan D. Kirk received his M.D. from Duke University in 1987 and his Ph.D. in Immunology from Duke in 1992. He completed his General Surgery Residency at Duke in 1995 and his multi-organ transplantation fellowship at the University of Wisconsin in 1997. He is a Diplomate of the American Board of Surgery and a Fellow of the American College of Surgeons.
From 1997 through 2001 he served as a Commander in the United States Navy and as a Principal Investigator at the Naval Medical Research Center in Bethesda, Maryland. In 1999, he became the inaugural Chief of the NIH intramural Solid Organ Transplant Program. He served as Chief of the Transplantation Surgery Section through 2001 and then joined the NIH faculty as a Senior Investigator and Chief of the NIDDK Transplantation Branch. He has recently joined the faculty at Emory University as Professor of Surgery and Pediatrics, and Scientific Director of the Emory Transplant Center.
Dr. Kirk's primary interests lie in the translation of transplantation tolerance induction strategies and immunosuppressive individualization/ minimization approaches to the clinic. He has been Principal Investigator on numerous clinical trials including early translational studies with alemtuzumab. His bibliography contains 160 scientific manuscripts and book chapters. He serves on the Editorial Boards of the American Journal of Transplantation, Transplantation, Transplantation Immunology and Human Immunology. He is an elected member of the Society of University Surgeons and the American Society of Clinical Investigation. In 2006, he was the recipient of the AST/Roche Clinical Science Investigator Award.
Dr. Kirk has been an active member of the AST and TTS since 1997 and currently serves on the AST Board of Directors.
Prof. Randall E. Morris, M.D.
- 2006-Present: Head of Therapeutic Sciences for Transplantation and Immunology in the Infectious Diseases, Transplantation and Immunology, Novartis Pharma AG, Switzerland.
- 2002-2006: Head of Transplantation Research and Head of Translational Medicine for Transplantation, NIBR, Switzerland.
2004-Present: Emeritus Professor of Cardiothoracic Surgery; Medicine and Surgery (by courtesy), Stanford University School of Medicine.
- 1983-2004: Director of the Laboratory for Transplantation Immunology and a professor of Cardiothoracic Surgery; Medicine and Surgery (by courtesy), Stanford University School of Medicine.
Major Laboratory and Clinical Research Projects:
- 1989-2004: Discovered and published the first efficacies of mycophenolate mofetil (RS-61443) and sirolimus for prevention of acute and chronic transplant rejection in rodents and monkeys
- 1993-1995: Discovered efficacy of sirolimus for prevention of restenosis after arterial balloon angioplasty.
- 1992-2000: First published the efficacy of a humanized form of anti-LFA-1 monoclonal antibody (efilizumab) for prevention monkey heart graft rejection. . 2003-2004: First publication on efficacy of the (JAK3) inhibitor, CP-690, 550, for prevention of acute transplant rejection.
- 2002-2005: Preclinical development and early clinical development of AEB071, a novel protein kinase C inhibitor AEB071.
- 1995-Present: Developed new methods to measure the effects of immunosuppressive drugs on immune cells (pharmacodynamics).
Return to the State of The Art Program
